AtriCure Reports Q3 Revenue and Receives FDA Clearance
What happened
AtriCure reported third-quarter 2026 revenue of $154.5 million, which was 15% higher than the previous year. The company also received FDA 510(k) clearance for its device. U.S. open ablation revenue increased 20.8% year over year, driven by the EnCompass Clamp and other products.
From tickerreport.com
Why it matters
The revenue growth was supported by increased adoption of AtriCure’s products in U.S. open ablation and appendage management businesses. Furthermore, AtriCure expects a new quality metric from the Society of Thoracic Surgeons to help support the adoption of its devices.
From tickerreport.com
Who's involved
- NasdaqStock exchange where AtriCure reports revenue
- FDARegulatory agency that granted 510(k) clearance
- Society of Thoracic SurgeonsMedical organization expected to adopt a new quality metric
- Center for Devices and Radiological HealthFormal division of the FDA
- United States of AmericaJurisdiction where AtriCure operates
Who could feel it
Possible knock-on effectsThese are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.
- Society of Thoracic SurgeonsSpeculative
The Society of Thoracic Surgeons might see increased demand for AtriCure's devices due to the adoption of a new quality metric.
- NasdaqSpeculative
Nasdaq might experience changes in market confidence and stock valuation following AtriCure's revenue reporting.